Ariah.bio, developed by AMK Biotech, is a biotechnology and research services brand focused on understanding the complexity of human tissue. It combines laboratory expertise, biology, computational analysis and artificial intelligence in an integrated facility, offering end-to-end tissue analysis for research and development. Its services include panel development, sample staining, high-plex tissue imaging, image and data acquisition, and computational analysis. Ariah develops specialized protocols to support reliable analysis of samples with 40 to 50 targets, helping researchers examine cellular interactions and identify biological patterns that may otherwise remain unseen.

The company serves pharmaceutical development, oncology research, clinical trials and surveillance, and skincare development. Its research and development work includes MaxiPath, a high-plex imaging approach intended to support cancer diagnosis, predict disease evolution and relapse risk, and inform targeted treatment. Ariah states that its combined imaging and computational workflow can reduce time, costs and biological resource use. The brand presents its work as contributing to improved wellbeing and life-saving discoveries, particularly in cancer research, and identifies itself as a France 2030 laureate and recipient of the 2024 AI & Health Trophy.